Novo Nordisk A/S ADR NOVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NOVA is a good fit for your portfolio.
News
-
Eight stock picks in AI, obesity drugs, -2-
-
Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500
-
This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
-
This weight-loss ETF has performed well in its -2-
-
Ozempic, similar weight-loss drugs don't increase suicide risk: EU regulator
-
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says
-
Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say
-
Wegovy's heart benefits are not just linked with weight loss, new study suggests
Trading Information
- Previous Close Price
- $117.50
- Day Range
- $116.50–119.00
- 52-Week Range
- $87.00–186.00
- Bid/Ask
- $119.00 / $119.50
- Market Cap
- $530.90 Bil
- Volume/Avg
- 311 / 0
Key Statistics
- Price/Earnings (Normalized)
- 47.07
- Price/Sales
- 16.96
- Dividend Yield (Trailing)
- 1.08%
- Dividend Yield (Forward)
- 1.37%
- Total Yield
- 1.88%
Company Profile
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Growth
- Total Number of Employees
- 60,000
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NOVA
|
SNY
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 47.07 | 9.56 | 87.16 |
Price/Book Value | 36.60 | 1.49 | 64.46 |
Price/Sales | 16.96 | 2.27 | 19.36 |
Price/Cash Flow | 32.51 | 11.11 | 90.55 |
Price/Earnings
NOVA
SNY
LLY
Financial Strength
|
Metric
|
NOVA
|
SNY
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.62 | 0.83 | 0.52 |
Current Ratio | 0.82 | 1.27 | 0.94 |
Interest Coverage | 192.15 | 11.03 | 14.13 |
Quick Ratio
NOVA
SNY
LLY
Profitability
|
Metric
|
NOVA
|
SNY
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 30.82% | 8.05% | 10.22% |
Return on Equity (Normalized) | 94.27% | 14.38% | 52.03% |
Return on Invested Capital (Normalized) | 72.84% | 10.85% | 19.27% |
Return on Assets
NOVA
SNY
LLY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lrslncgss | Qrqdp | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndmwlpksj | Bnzspyx | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cvwlvrb | Hzdstfq | $98.8 Bil | |
MRNA
| Moderna Inc | Nbjrtgpm | Rkqlv | $38.8 Bil | |
ARGX
| argenx SE ADR | Bzmxqtj | Cxdh | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Dwxcrzqb | Kjd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xgjdddhsf | Gfmbwb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wpnmtzvj | Xqchj | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Kxrvnhdsh | Yxfwms | $12.4 Bil | |
INCY
| Incyte Corp | Kprwhlw | Bbqqr | $11.9 Bil |